We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tests Combined for Early Diagnosis of Liver Disease

By LabMedica International staff writers
Posted on 20 Sep 2012
Print article
A recently devised test could be used in primary care to diagnose liver fibrosis and cirrhosis in high-risk populations more easily than at present.

Known as the Southampton traffic light test (STL), it combines the fibrosis markers procollagen-3 N-terminal peptide (P3NP) and hyaluronic acid (HA), along with routine liver function tests in a clinical algorithm that can be used in an outpatient clinic.

Scientists at University of Southampton (UK) studied 1,038 consecutive patients with suspected liver disease, in whom the routine full blood count, liver function tests, and analysis of the serum HA or collagen P3NP had been performed as part of routine diagnosis, between July 2003 and November 2009.

The fibrosis markers were assayed using commercial immunoassays. The assay for P3NP was from Orion Diagnostica (Espoo, Finland) and the HA assay was from Corgenix Inc. (Broomfield, CO, USA). The STL is a clinically derived heuristic, based on the scientists experience using fibrosis markers in the liver clinic. To aid interpretation for the study, the results were categorized into three grades: green, amber, and red, as follows: if the HA is greater than 30 µg/L or P3NP is greater than 5.5 µg/L, this equals a score of plus one. If the HA is greater than 75 µg/L, this equal a score of plus two and a platelet count of less than 150 ×109/L gives a score of plus one.

The red means that the patient had a score of two or more and has liver scarring (fibrosis) and may even have cirrhosis. The green means the score is zero and that there is no cirrhosis and the patient is highly unlikely to die from liver disease over the next five years. The amber means a score of one and there is at least a 50:50 chance of scarring with a significant possibility of death within five years, and patients are advised to stop drinking to avoid further disease and death.

The test was given to over 1,000 patients, and their progress was carefully followed and monitored afterwards, in some cases over several years, to assess the accuracy of the test in predicting whether they developed liver fibrosis or cirrhosis. The test proved to be accurate in severe liver disease, and while not a substitute for clinical judgment or other liver function tests, can provide physicians with an objective means to accurately assess the potential severity of liver fibrosis in high-risk patients, such as heavy drinkers, those with type II diabetes, or obese people.

Nick Sheron, MD, FRCP, the senior author said, "We are reliant on general practitioners detecting liver disease in the community so they can intervene to prevent serious liver problems developing, but so far we haven't been able to give them the tools they need to do this. We hope that this type of test for liver scarring may start to change this because the earlier we can detect liver disease, the more liver deaths we should be able to prevent." The study was published in September 2012 in the online edition of the British Journal of General Practice (BJGP).

Related Links:
University of Southampton
Orion Diagnostica
Corgenix Inc.


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.